Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual M
Go back to Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual M| (NASDAQ: NRIX) | Delayed: 18.70 +1.15 (6.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.55 | 52 Week High | $ | |||
| Open | $17.83 | 52 Week Low | $ | |||
| Day High | $18.85 | P/E | N/A | |||
| Day Low | $17.83 | EPS | $ | |||
| Volume | 538,735 | |||||
